Prevalence and determinants of microalbuminurea among type 2 diabetes mellitus patients, Baghdad, Iraq, 2013

Abstract EN

Microalbuminuria (MAU) is an early marker of diabetic nephropathy (DN), which accounts for a significant reduction in life expectancy of diabetic patients.

The progression of DN from the appearance of clinical proteinuria to end stage renal failure is usually irreversible.

Increased levels of urinary albumin secretion may represent a more generalized vascular damage.

This is the first study conducted in Iraq to determine the prevalence and potential risk factors of MAU among Type 2 diabetes mellitus (T2DM) patients.

A cross-sectional study was conducted on a systematic random sample of 224 eligible T2DM patients aged 25–64 years attending a DM clinic in Baghdad.

A questionnaire was developed to gather basic and clinical data, besides anthropometric measurements, and laboratory assessment of lipid profile, HbA1c, serum creatinine, albumin, and microalbumin/creatinin in urine.

MAU was defined as albumin/creatinine ratio 30–300 mg/g on two occasions.

Only 36 cases (16.1%) had MAU.

A statistical significant association found between MAU and educational level (P = 0.009), family history of hypertension (P = 0.024) and DN (P = 0.013), history of hypertension (P = 0.001), duration of angiotensinconverting- enzyme inhibitor drug intake in hypertensive patients (P = 0.001), body mass index (BMI) (P = 0.014), and waist to hip ratio (P = 0.006).

Logistic regression analyses revealed two independent risk factors influencing MAU: diastolic blood pressure [odds ratio (OR) = 1.08, 95% confidence interval (CI): 1.007–1.118] and BMI (OR = 1.17, 95 % CI : 1.037–1.220).

The prevalence of MAU is not low among DM patients.

Mandatory screening of all DM patients and amelioration of the assigned significant risk factors are recommended.